Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Mean cell haemoglobin concentration, Mean cell volume, Mean platelet volume, Monocyte count, Neutrophil count
Clinical narrative: Eosinophils were 599/dropped down and the Absolute Eosinophils count was 510/Eosinophils were 360; This is a spontaneous report received from a contactable reporter(s) (Pharmacist) from medical information team for a Pfizer sponsored program. The reporter is the patient.  A 69 year-old male patient received bnt162b2 (COMIRNATY), intramuscular, administered in arm left, administration date 22Mar2021 11:00 (Lot number: EN6206) at the age of 69 years as dose 2, 0.3 ml single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose: 01, dose: 0.3ml, Time: 11:00 AM, Anatomical site if injection: Left arm, Route of administration: Intramuscular, Batch/Lot number: EL9267), administration date: 01Mar2021, when the patient was 69 years old, for Covid-19 immunization. The following information was reported: EOSINOPHIL COUNT ABNORMAL (non-serious) with onset 09Apr2021, outcome "unknown", described as "Eosinophils were 599/dropped down and the Absolute Eosinophils count was 510/Eosinophils were 360". The event "eosinophils were 599/dropped down and the absolute eosinophils count was 510/eosinophils were 360" was evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section.  Additional information:Serious: No.Retired Pharmacist calling on behalf of himself.He received his 2nd dose of the Pfizer Covid-19 Vaccine on 22Mar2021. 2 weeks after, he experienced eosinophilia, that went on for 6 weeks. He received his Booster Dose of the vaccine last week and has had no further blood work.Caller is asking has eosinophilia been reported after receiving the Pfizer Covid-19 Vaccine.Reporter seriousness for Eosinophilia: Unspecified.Expiry Date of Pfizer Covid Vaccine: Unknown.Other Products: No.Patient History: No.Investigation Assessment: Yes.He is not sure if it is an adverse reaction. He looked in the literature and did not see anything about Eosinophilia. This is the first time in his life that he has had Eosinophilia. He received second dose of COVID vaccine on 22Mar2021. He had bloodwork on 09Apr2021 and the Eosinophils were 599. On 07May2021 it had dropped down and the Absolute Eosinophils count was 510. Then it disappeared. On CBC on 01Oct2021 Eosinophils were 360. He got the booster last week. He has not had any more bloodwork or CBC after the booster.Seriousness Criteria: unknown. He is not quite sure. His internal doctor thinks it might be related to allergies and is going to refer him to a hematologist to rule out blood disorder.Phone: not provided when queried. Additional Vaccines Administered on Same Date of the Pfizer Suspect: None.Time of Onset: Two weeks after second Pfizer Covid Vaccine.Physician Office: His internal doctor thinks it might be related to allergies and is going to refer him to a hematologist to rule out blood disorder. Prior Vaccinations (within 4 weeks): Not Provided.AE(s) following prior vaccinations: None.Patients Medical History: None.Family Medical History Relevant to AE(s): Not Provided.Did the patient provide information to you regarding the reported adverse event(s) with the use of the product: No.Prior vaccinations: None.Concomitant drugs: None.Patients medical history: None.Relevant tests: None.Specific relevant test for thromboembolic events with thrombocytopenia: None.Vitamin D3,1,25(OH)2 indicates both endogenous production ad supplementation. Vitamin D2,1,25(OH)2 is indicator of exogenous sources, such as diet or supplementation. Interpretation and therapy are based on measurement of vitamin D,1,25(OH)2, total.This test was developed, and its analytical performance characteristics have been determined by quest diagnostics withheld. It has not been cleared or approved by the FDA. This assay has been validated pursuant to CLIA regulations and is used for clinical purposes.Currently, no consensus exists regarding use of hemoglobin A1c for diagnosis of diabetes in children.According to American diabetes association (ADA) guidelines, hemoglobin A1c< 7.0% represents optimal control in non-pregnant diabetic patients. Different metrics may apply to specific patient populations. Standards of medical care in diabetes(ADA).  No follow-up attempts are possible. No further information is expected.